{"ticker": {"uuid": "7d7e54ad-3151-4e56-8182-5daf90cc71d7", "symbol": "ADPT", "name": "Adaptive Biotechnologies Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "articles": [{"title": "Planned 5,000-share stock sale for ADPT (NASDAQ: ADPT)", "summary": "Susan Bobulsky plans to sell 5,000 shares of Adaptive Biotechnologies Corp (ADPT) common stock, valued at $114,500, with a planned sale date of July 16, 2026. The shares originate from previously exercised stock options and will be sold through Morgan Stanley Smith Barney LLC Exe", "url": "https://www.stocktitan.net/sec-filings/ADPT/144-adaptive-biotechnologies-corp-sec-filing-617c6c8a7500.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:41:34", "published_display": "16 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies stock hits 52-week high at 22.81 USD", "summary": "Adaptive Biotechnologies (NASDAQ: ADPT) stock reached a new 52-week high of $22.81, reflecting a 108.77% increase over the past year. This surge is supported by strong revenue growth and investor confidence in the company's biotechnology focus, despite an InvestingPro analysis su", "url": "https://www.investing.com/news/company-news/adaptive-biotechnologies-stock-hits-52week-high-at-2281-usd-93CH-4794128", "source_name": "Investing.com", "published_at": "2026-07-15T20:16:31", "published_display": "15 Jul 2026 20:16", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOWnJkZk9KRVFBUG9ub3FYWVdqSERiR1Q3b0NCOExsQmdSUHhJREtXWTJMNkF1Y0tGVkxFcnJqZTV5YWI2RXZibEpoSkt0dzBES2FBbWljc2F5dTBYVVRNTHFldWY1bVEzeU8yZzJBM3JpelhfWWhDc0U4cWlDZTJ2SVZvV21rUHFDU1JVZTNEcGlPaVlmWFc1SkVuTExFUUp5REVtM2czQVJyZXktanNVOWhsWVZfZ3MxSzhZOGxuWjl6cHRTWDYwVjN3?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-12T22:38:00+00:00", "published_display": "12 Jul 2026 22:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Message Do Insider Sales Send About Adaptive Biotechnologies (ADPT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNNWxwRjBUT0FMbWNYVWVJUUVLbTRxZjBYZC1vT1ZpUGF3R0dFQ2tYX25VdnJXcWh1M3o5SVp0Rkh1TTNfRW1JX0FXalhJWHktYm5aNTRuYVRsVTM0ZktGQVpRZHAzT01ScWp1ak1PN2tFVU5JOThKMTg3UFI1VGx1OTdSY1FqUTRHVVlTY1haUUF3LTFuUjNyQkpLVnZTUE8zZnllSGJrcXM?oc=5", "source_name": "Kavout | AI", "published_at": "2026-07-11T13:13:31+00:00", "published_display": "11 Jul 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (ADPT) Stock Looks Reasonable On Cash Flow Yet Rich On Sales", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T21:34:22+00:00", "published_display": "10 Jul 2026 21:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies to report Q2 2026 results on July 29", "summary": "Adaptive Biotechnologies Corporation is scheduled to release its financial results for the second quarter of 2026 after the market closes on July 29, 2026. A conference call will follow to discuss the results, which will be accessible via webcast on the company's website. The com", "url": "https://scanx.trade/stock-market-news/companies/adaptive-biotechnologies-to-report-q2-2026-results-on-july-29/45185327", "source_name": "scanx.trade", "published_at": "2026-07-10T03:39:10", "published_display": "10 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/adaptive-biotechnologies-report-second-quarter-200500015.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T20:05:00+00:00", "published_display": "09 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies sets July 29 results call after market close", "summary": "Adaptive Biotechnologies (ADPT) announced it will report its second-quarter 2026 financial results after market close on July 29, 2026. The company will also host a webcasted conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, with the audio accessible via its ", "url": "https://www.stocktitan.net/news/ADPT/adaptive-biotechnologies-to-report-second-quarter-2026-financial-h591ajqmldhu.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:07:32", "published_display": "09 Jul 2026 20:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADPT Maintained by Morgan Stanley -- Price Target Raised to $20.", "summary": "Morgan Stanley has reiterated its \"Equal-Weight\" rating on Adaptive Biotechnologies (ADPT) and increased its price target from $18 to $20. Despite this, GuruFocus assesses ADPT as significantly overvalued with a GF Value\u2122 of $10.05 against a current price of $21.77, and insider a", "url": "https://www.gurufocus.com/news/8951990/adpt-maintained-by-morgan-stanley-price-target-raised-to-2000", "source_name": "GuruFocus", "published_at": "2026-07-09T17:07:32", "published_display": "09 Jul 2026 17:07", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (ADPT) Faces Russell Index Removals, Does It Look Fairly Valued?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T14:34:04+00:00", "published_display": "09 Jul 2026 14:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies Insider Sold Shares Worth $8,501,149, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/adaptive-biotechnologies-insider-sold-shares-073506156.html", "source_name": "MT Newswires", "published_at": "2026-07-08T07:35:06+00:00", "published_display": "08 Jul 2026 07:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive biotechnologies CSO Harlan Robins sells $8.5m in stock By Investing.com", "summary": "Harlan S. Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 386,240 shares of the company's common stock for approximately $8.5 million on July 2, 2026. These sales were conducted under a pre-arranged trading plan and occurred near the stock's ", "url": "https://ng.investing.com/news/stock-market-news/adaptive-biotechnologies-cso-harlan-robins-sells-85m-in-stock-93CH-2590068", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T00:39:49", "published_display": "08 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Adaptive Biotechnologies Corp For: 7 July By Investing.com", "summary": "This article announces the filing of a Form 4 for Adaptive Biotechnologies Corp on July 7, 2026. The content provides the headline in multiple sections, indicating that a Form 4 document has been filed for the company with the ticker ADPT, mentioning a stock price change of -3.17", "url": "https://za.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-for-7-july-93CH-4359541", "source_name": "Investing.com South Africa", "published_at": "2026-07-07T23:39:49", "published_display": "07 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CSO sells 386,240 Adaptive Biotechnologies (NASDAQ: ADPT) shares under plan", "summary": "Adaptive Biotechnologies Corp's Chief Scientific Officer, Harlan S. Robins, sold 386,240 shares of common stock on July 2, 2026. These sales were executed in two blocks at weighted-average prices of $21.74 and $22.45 per share, totaling approximately $8.50 million. The transactio", "url": "https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-7bafcbf83a53.html", "source_name": "Stock Titan", "published_at": "2026-07-07T23:11:10", "published_display": "07 Jul 2026 23:11", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Adaptive Biotechnologies Corp For: 6 July By Investing.com", "summary": "This article reports on a Form 4 filing for Adaptive Biotechnologies Corp on July 6th. It is a brief announcement indicating the availability of the filing from Investing.com. The content primarily consists of navigation, advertisements, and market data, with the core substance b", "url": "https://uk.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-for-6-july-93CH-4758620", "source_name": "Investing.com UK", "published_at": "2026-07-07T11:08:57", "published_display": "07 Jul 2026 11:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies Insider Sold Shares Worth $2,157,683, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/adaptive-biotechnologies-insider-sold-shares-075816175.html", "source_name": "MT Newswires", "published_at": "2026-07-07T07:58:16+00:00", "published_display": "07 Jul 2026 07:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Russell Index Removal Reshape the Bull Case for Adaptive Biotechnologies (ADPT)?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Adaptive Biotechnologies Corp. \u2013 DUS:1HM", "summary": "The article focuses on the enterprise value to EBIT forward for Adaptive Biotechnologies Corp. (DUS:1HM), listed on the Dusseldorf Stock Exchange. It provides a financial overview and market data for the company's stock.", "url": "https://www.tradingview.com/symbols/DUS-1HM/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T01:10:13", "published_display": "07 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies CCO Susan Bobulsky sells $10,714 in stock", "summary": "Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 487 shares of the company's common stock for $10,714 on July 1, 2026, as per a Rule 10b5-1 trading plan. The sale occurred while the stock was near its 52-week high and considered overvalued by InvestingPro.", "url": "https://www.investing.com/news/insider-trading-news/adaptive-biotechnologies-cco-susan-bobulsky-sells-10714-in-stock-93CH-4778000", "source_name": "Investing.com", "published_at": "2026-07-07T01:08:57", "published_display": "07 Jul 2026 01:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies CPO Francis Lo sells $2.16m in stock", "summary": "Francis Lo, Chief People Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold over $2.16 million in stock across two days in July 2026, executed under a Rule 10b5-1 trading plan. Concurrently, Lo acquired shares worth approximately $661,885 through exercising stock option", "url": "https://www.investing.com/news/insider-trading-news/adaptive-biotechnologies-cpo-francis-lo-sells-216m-in-stock-93CH-4778001", "source_name": "Investing.com", "published_at": "2026-07-07T01:08:57", "published_display": "07 Jul 2026 01:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells 487 shares under 10b5-1 plan", "summary": "Adaptive Biotechnologies Corp's Chief Commercial Officer, Susan Bobulsky, sold 487 shares of common stock at $22.00 per share, totaling $10,714. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025. Following the sale, she still", "url": "https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-dac1586f695e.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:08:57", "published_display": "06 Jul 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (ADPT) CPO trades 95,842 shares under 10b5-1 plan", "summary": "Adaptive Biotechnologies Corp's Chief People Officer, Francis Lo, executed pre-planned stock option exercises and share sales totaling 95,842 shares between July 1-2, 2026. These transactions, made under a Rule 10b5-1 trading plan adopted in September 2025, involved selling share", "url": "https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-4793612f8acd.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:08:57", "published_display": "06 Jul 2026 23:08", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Adaptive Biotechnologies Corp. \u2013 DUS:1HM", "summary": "This article provides financial information for Adaptive Biotechnologies Corp. (DUS:1HM) on the Dusseldorf Stock Exchange. It specifically highlights the \"Price to sales forward\" metric under its financials section. The content is brief and appears to be a stub or a section of a ", "url": "https://www.tradingview.com/symbols/DUS-1HM/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T22:08:57", "published_display": "06 Jul 2026 22:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Adaptive Biotechnologies Corp. \u2013 HAM:1HM", "summary": "This article displays the \"Price to sales forward\" financial metric for Adaptive Biotechnologies Corp. (HAM:1HM) as listed on the Hamburg Stock Exchange. The current market status is closed, with no trades observed. The data is provided by ICE Data Services and FactSet Research S", "url": "https://www.tradingview.com/symbols/HAM-1HM/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T01:39:30", "published_display": "06 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Adaptive Biotechnologies Corp. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold stocks of Adaptive Biotechnologies Corp. (1HM), traded on the Frankfurt Stock Exchange. The ETFs are sorted by their market value of the Adaptive Biotechnologies Corp. shares they hold, providing details such as is", "url": "https://www.tradingview.com/symbols/FWB-1HM/etfs/", "source_name": "TradingView", "published_at": "2026-07-04T11:41:55", "published_display": "04 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADPT - Adaptive Biotechnologies Corp Earnings", "summary": "This article provides a comprehensive financial overview of Adaptive Biotechnologies Corp (ADPT), detailing its stock performance, key financial metrics, and earnings information. It highlights the company's recent earnings surprise, insider and institutional ownership, and vario", "url": "https://finviz.com/stock?t=ADPT&p=d&ty=ea&utm_source=averageinsider&utm_medium=button&utm_content=ratio_drilldown&utm_term=ADPT", "source_name": "Finviz", "published_at": "2026-07-03T10:10:03", "published_display": "03 Jul 2026 10:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harlan Robins sells 116,160 ADPT shares (ADPT) per Form 144 filing", "summary": "Harlan Robins, an insider at Adaptive Biotechnologies Corp (ADPT), filed a Form 144 disclosing the proposed and recent sales of 116,160 shares of Common Stock. This filing details sales on three separate occasions in the past three months, with values totaling over $1.9 million. ", "url": "https://www.stocktitan.net/sec-filings/ADPT/144-adaptive-biotechnologies-corp-sec-filing-653c4907e102.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:10:13", "published_display": "02 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Francis Lo plans ADPT share sales (NASDAQ: ADPT) under Form 144", "summary": "Francis Lo has filed a Form 144 to report proposed dispositions of Adaptive Biotechnologies Corp (ADPT) common stock. The filing details an exercise of stock options for 179,039 shares and a grant of 20,221 Restricted Stock Units, along with two prior 10b5-1 sales totaling over $", "url": "https://www.stocktitan.net/sec-filings/ADPT/144-adaptive-biotechnologies-corp-sec-filing-c0394246a84b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:41:04", "published_display": "01 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADPT (NASDAQ: ADPT) insider sold shares via 10b5-1 plan in June 2026", "summary": "An insider at Adaptive Biotechnologies Corp (NASDAQ: ADPT), Susan Bobulsky, executed three 10b5-1 sales in June 2026, totaling 21,000 shares with combined proceeds of $395,500. These routine transactions were filed via Form 144 and do not indicate new material information about t", "url": "https://www.stocktitan.net/sec-filings/ADPT/144-adaptive-biotechnologies-corp-sec-filing-fa9786851527.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:41:04", "published_display": "01 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive biotechnologies CCO Sharon Benzeno sells over $3.5m in stock", "summary": "Sharon Benzeno, CCO of Adaptive Biotechnologies Corp, sold over $3.5 million worth of company stock in late June through a pre-arranged trading plan. These sales followed the exercise of stock options worth approximately $885,555. The company recently reported strong Q1 2026 reve", "url": "https://m.za.investing.com/news/stock-market-news/adaptive-biotechnologies-cco-sharon-benzeno-sells-over-35m-in-stock-93CH-4350913?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T08:38:58", "published_display": "01 Jul 2026 08:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Adaptive Biotechnologies Corp For: 30 June By Investing.com", "summary": "This article reports on the filing of Form 4 for Adaptive Biotechnologies Corp for the period ending June 30. It focuses solely on this regulatory filing, indicating an insider transaction or change in ownership that companies are required to disclose. The article is very brief, ", "url": "https://au.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-for-30-june-93CH-4512472", "source_name": "Investing.com Australia", "published_at": "2026-07-01T08:38:58", "published_display": "01 Jul 2026 08:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (ADPT) CCO trades shares under 10b5-1 plan", "summary": "Sharon Benzeno, Chief Commercial Officer for Immune Medicine at Adaptive Biotechnologies (ADPT), exercised stock options and sold a total of 165,802 shares in open-market transactions on June 26 and 29, 2026. These transactions, executed under a pre-arranged Rule 10b5-1 trading p", "url": "https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-4c42b6648cad.html", "source_name": "Stock Titan", "published_at": "2026-07-01T08:38:58", "published_display": "01 Jul 2026 08:38", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Adaptive Biotechnologies Corp For: 29 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Adaptive Biotechnologies Corp (ADPT) for June 29. The brief piece indicates insider trading activity for the company on the specified date.", "url": "https://ng.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-for-29-june-93CH-2579136", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T01:11:59", "published_display": "01 Jul 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Adaptive Biotechnologies (NASDAQ: ADPT) exercises options and sells shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOcHpOSWFNQVVNRi1rVmlxTDhVa05Mdlh1R2doaU9wejdOVzZKLVRnNUxyR3JZMWZsT3BHTGs3bzE4Y1I4NS1wWnRJa29kYVRuOGFoTU43X2dtV2t5VkZCelhTSEtmc0VLUzNiZFhYQnBWekdpNW5RN1dpblFuQ0w0MHl5ZVd0dy1Hb3hacTZIbVVsWl8xdkdBdUdZSnZHbEtRME5oUkVZNUkwWG5ZT3BYV1R1TUJNczF4YzUyX3ZZenE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider sells shares under 10b5-1 plan \u2014 ADPT (NASDAQ: ADPT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPWEFnZmJCUFg4OC1mc1RSdzJpa1dseFlDb19zcDdWN1VBQWNNVEM5eDhoMTNfMzUzRThuQUdnNEhWY216Z1NBdlB3RTYxal9SV01PUmhtdG04N2ZYei01Nkhxa0w5bFI4RzF0c0FaVFlRdXREc2czbVVrOG1vem5ReUFxbFBTSmdzN1RuR3YzTzl5QU1LYWlyRHdyU2tscVNJYWUxNnY5Sk9Sdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOeVdaMlFzeXBIZHJ6d0V4X3lObzUyX0wzUUFYWlJ4Q1lfV2F2bFY2LWRmaTNNMUpSWV9ZN2todkQxVkJKUGRsYjBxYjN3VDhraGp0bkdVbGRNbmlPWTZBZ0EyZGxDV3Q3UC1nc18tSDU4dHc3V0hYUGVCS1I0OWd6ZkVqTE1NSGlYN3dKT0hDemxpc3prejBKMTkzdw?oc=5", "source_name": "Market source", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Adaptive Biotechnologies Corp SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPLUVoeXBGWFZMWTdDT01wZ3JxWFdnWEl3bEwtQ253Z1pUYVBhd280RkY5aGNkMzhtYkNPODBwU1pZa3RIUmxHOHByTTBRanZNZTQyQW15a3l4U1Qwdk5aSmxqZG8ybmhkSXhfY2xaeE4tMkpYV1F3UU9yQW53d3l0M2lIb1BzZXF4VHNrY1VmODZ6em9YLS04N3F6S0xwZVE4Y3NTRjloLVhfQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies Issues $345 Million Convertible Notes", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/adaptive-biotechnologies-issues-345-million-213858102.html", "source_name": "MT Newswires", "published_at": "2026-06-22T21:38:58+00:00", "published_display": "22 Jun 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies Insider Sold Shares Worth $1,847,942, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/adaptive-biotechnologies-insider-sold-shares-081002684.html", "source_name": "MT Newswires", "published_at": "2026-06-18T08:10:02+00:00", "published_display": "18 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies raises $300M zero-interest debt, buys back stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNcWxXcDFKaDM2VXBYZ0lHZGd2TEhpTFoxOTBRdlNHZjNWMXliWTJhRWdKRDFDemNRRHQ0cVRRV0F1U3V4YVJiZnVwdHRZLWhwR01oSW83eVpsZTRxS0poc2tXYi01NURXSWtkNmFXY08xRHNncVl0NU1QRHNRTEplOHJrSHBjaTIzSnpKQzB6T0YxWExVLXVLemdrZU9ZUXYwazVhZWdMOWgzMGY1dVpzNzBraDQ4ZWdQVEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies lines up $250M note deal to repay debt, buy back shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOOVhCd1BNYWRMOHNwQU9pZ2l6ci1OTnFDVnN6ZjBtWHpNUUJGbEtvNlg5WllYcF9MTFNPVWZfTmF6MktsN05SX2ZwTV9yTVFlaVJuSmxlbW1HVi1wR1VZMlBTRUNRWE56MXZNN3BVbW9UdmJBTTdfZmZGeDdZaE8zYXVFNVo3S3B5RUo5Q3pFcFhfaEUwUHRlSDZOZkt4NWdBVUR2aGVkVzZhMGVWbUtMV1VJSVhtSXNmcThaZ2hTYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (NASDAQ: ADPT) to sell $250M converts and explore MRD\u2013Immune Medicine split", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNcjRaOVF5SERnWHhfczlsQ1RSMTNTaTVsa3lKWnhXZGJsOUVfdWV5dHVQTzRnVVZVNEpPV3Z0S2JXNXlmQ016VUFReXVtamdycXhVeE5XdUx0N0tUQWR3cGVUQ1ozOFVyajZsc3UxTTBYUTlTeDFaTHhYWGJTdjZtNE52bGRNUndtRlZ5cjEwTzJGZ0ZtNmQ4anBOWElZSDNwN1ZVR0tjcWdwVkNEX0lYdE1PTkhBODluYXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPRHNaNHJZTmk5SnVxdk85cWw1SnFnVEc1WnA4WG5tWFYxVDRmVTdEemNZMWw3OTZwLTR3MUZIUkpzUGZkZnoxTHZqb2twaGprRS1RZzRUT1Q3M1k0Z3pQX01pdW9wVlYyVXMxS3RuMk1uZFZ2N2wtWEQzUVIxdXVwaUg5NlBQRElsQnVta09xenhuWHZ0NUdxREl3YlpIM2tLRFZ3bQ?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Adaptive Biotechnologies (ADPT) Narrative Is Shifting Around A US$20 Fair Value Anchor", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPVWpNbm1FamlxSkhFQ1ctOVRSWWMyMWlsZGtnekNvRVhfX0lzSGFWdV9XU3pmaDlaYjlIeF9YdDJHS0pob0RxVllHQUxVUHAyV19Lb0lzYW1ZZDJSQmVvcENPb3VnZjNDWHJJaUZCaUZ6Ni1ETWJmWVNCUkpoQ2R6bmcxSmRqNG1RSWJKNmp0TmlLWTMyN2JXR2hraDRaWkFHTXp3bnN3OHhnWm01T3pNQW9sWQ?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Adaptive Biotechnologies (ADPT) Attractively Priced After Recent Share Price Weakness?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive lifts 2026 MRD outlook after $70.9M quarter, 41% test gain", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxONUQ2ZzVob3JoMm5Wa29HdjBacERGaWdfXzRUSi1qYWp0UTdQSXpPcFpWdS11NzR4T3pPY0I0Y21vUUFiSmUwTXZOMVJEQmhMLXlvNnNlU3ZlRGUtX3hEenpiT2cyYzNoLUF6QkVuczlZT0dIc1JnYU1Dc0JWeS1BVnJtYXNxck9Sb212Y2FfMzVIaWVEUWRZbXVkMzhldk1Ob2Z0QXd3cDdHYnQ5VllQbHh1WGpTTUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWEVXNllESWhPWDllcG4wMXFWZTloOTNZSXlIZHB4R1dMbEI1Q2VCTHJpdEFaQkJPWnZGb1dhWW10SWhScGhNUndwYTdMY282SWZ0QUtxYUlYUngwdXJWa2g1Ym5QQ2Z2M1o5cEtkRzFYVDBKemJycU9Jb1VUckJVRDhkel9Tb3BBTG1YZU5FdU54V1FMX19ReXZoSFE1VVFOWWdpZUY1U1k?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sale At Adaptive Biotechnologies Versus clonoSEQ Growth And Valuation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Planned 5,000-share stock sale for ADPT (NASDAQ: ADPT)", "summary": "Susan Bobulsky plans to sell 5,000 shares of Adaptive Biotechnologies Corp (ADPT) common stock, valued at $114,500, with a planned sale date of July 16, 2026. The shares originate from previously exercised stock options and will be sold through Morgan Stanley Smith Barney LLC Exe", "url": "https://www.stocktitan.net/sec-filings/ADPT/144-adaptive-biotechnologies-corp-sec-filing-617c6c8a7500.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:41:34", "published_display": "16 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies stock hits 52-week high at 22.81 USD", "summary": "Adaptive Biotechnologies (NASDAQ: ADPT) stock reached a new 52-week high of $22.81, reflecting a 108.77% increase over the past year. This surge is supported by strong revenue growth and investor confidence in the company's biotechnology focus, despite an InvestingPro analysis su", "url": "https://www.investing.com/news/company-news/adaptive-biotechnologies-stock-hits-52week-high-at-2281-usd-93CH-4794128", "source_name": "Investing.com", "published_at": "2026-07-15T20:16:31", "published_display": "15 Jul 2026 20:16", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOWnJkZk9KRVFBUG9ub3FYWVdqSERiR1Q3b0NCOExsQmdSUHhJREtXWTJMNkF1Y0tGVkxFcnJqZTV5YWI2RXZibEpoSkt0dzBES2FBbWljc2F5dTBYVVRNTHFldWY1bVEzeU8yZzJBM3JpelhfWWhDc0U4cWlDZTJ2SVZvV21rUHFDU1JVZTNEcGlPaVlmWFc1SkVuTExFUUp5REVtM2czQVJyZXktanNVOWhsWVZfZ3MxSzhZOGxuWjl6cHRTWDYwVjN3?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-12T22:38:00+00:00", "published_display": "12 Jul 2026 22:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Message Do Insider Sales Send About Adaptive Biotechnologies (ADPT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNNWxwRjBUT0FMbWNYVWVJUUVLbTRxZjBYZC1vT1ZpUGF3R0dFQ2tYX25VdnJXcWh1M3o5SVp0Rkh1TTNfRW1JX0FXalhJWHktYm5aNTRuYVRsVTM0ZktGQVpRZHAzT01ScWp1ak1PN2tFVU5JOThKMTg3UFI1VGx1OTdSY1FqUTRHVVlTY1haUUF3LTFuUjNyQkpLVnZTUE8zZnllSGJrcXM?oc=5", "source_name": "Kavout | AI", "published_at": "2026-07-11T13:13:31+00:00", "published_display": "11 Jul 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (ADPT) Stock Looks Reasonable On Cash Flow Yet Rich On Sales", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T21:34:22+00:00", "published_display": "10 Jul 2026 21:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies to report Q2 2026 results on July 29", "summary": "Adaptive Biotechnologies Corporation is scheduled to release its financial results for the second quarter of 2026 after the market closes on July 29, 2026. A conference call will follow to discuss the results, which will be accessible via webcast on the company's website. The com", "url": "https://scanx.trade/stock-market-news/companies/adaptive-biotechnologies-to-report-q2-2026-results-on-july-29/45185327", "source_name": "scanx.trade", "published_at": "2026-07-10T03:39:10", "published_display": "10 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/adaptive-biotechnologies-report-second-quarter-200500015.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T20:05:00+00:00", "published_display": "09 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies sets July 29 results call after market close", "summary": "Adaptive Biotechnologies (ADPT) announced it will report its second-quarter 2026 financial results after market close on July 29, 2026. The company will also host a webcasted conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, with the audio accessible via its ", "url": "https://www.stocktitan.net/news/ADPT/adaptive-biotechnologies-to-report-second-quarter-2026-financial-h591ajqmldhu.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:07:32", "published_display": "09 Jul 2026 20:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADPT Maintained by Morgan Stanley -- Price Target Raised to $20.", "summary": "Morgan Stanley has reiterated its \"Equal-Weight\" rating on Adaptive Biotechnologies (ADPT) and increased its price target from $18 to $20. Despite this, GuruFocus assesses ADPT as significantly overvalued with a GF Value\u2122 of $10.05 against a current price of $21.77, and insider a", "url": "https://www.gurufocus.com/news/8951990/adpt-maintained-by-morgan-stanley-price-target-raised-to-2000", "source_name": "GuruFocus", "published_at": "2026-07-09T17:07:32", "published_display": "09 Jul 2026 17:07", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (ADPT) Faces Russell Index Removals, Does It Look Fairly Valued?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T14:34:04+00:00", "published_display": "09 Jul 2026 14:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies Insider Sold Shares Worth $8,501,149, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/adaptive-biotechnologies-insider-sold-shares-073506156.html", "source_name": "MT Newswires", "published_at": "2026-07-08T07:35:06+00:00", "published_display": "08 Jul 2026 07:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive biotechnologies CSO Harlan Robins sells $8.5m in stock By Investing.com", "summary": "Harlan S. Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 386,240 shares of the company's common stock for approximately $8.5 million on July 2, 2026. These sales were conducted under a pre-arranged trading plan and occurred near the stock's ", "url": "https://ng.investing.com/news/stock-market-news/adaptive-biotechnologies-cso-harlan-robins-sells-85m-in-stock-93CH-2590068", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T00:39:49", "published_display": "08 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Adaptive Biotechnologies Corp For: 7 July By Investing.com", "summary": "This article announces the filing of a Form 4 for Adaptive Biotechnologies Corp on July 7, 2026. The content provides the headline in multiple sections, indicating that a Form 4 document has been filed for the company with the ticker ADPT, mentioning a stock price change of -3.17", "url": "https://za.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-for-7-july-93CH-4359541", "source_name": "Investing.com South Africa", "published_at": "2026-07-07T23:39:49", "published_display": "07 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CSO sells 386,240 Adaptive Biotechnologies (NASDAQ: ADPT) shares under plan", "summary": "Adaptive Biotechnologies Corp's Chief Scientific Officer, Harlan S. Robins, sold 386,240 shares of common stock on July 2, 2026. These sales were executed in two blocks at weighted-average prices of $21.74 and $22.45 per share, totaling approximately $8.50 million. The transactio", "url": "https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-7bafcbf83a53.html", "source_name": "Stock Titan", "published_at": "2026-07-07T23:11:10", "published_display": "07 Jul 2026 23:11", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Adaptive Biotechnologies Corp For: 6 July By Investing.com", "summary": "This article reports on a Form 4 filing for Adaptive Biotechnologies Corp on July 6th. It is a brief announcement indicating the availability of the filing from Investing.com. The content primarily consists of navigation, advertisements, and market data, with the core substance b", "url": "https://uk.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-for-6-july-93CH-4758620", "source_name": "Investing.com UK", "published_at": "2026-07-07T11:08:57", "published_display": "07 Jul 2026 11:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies Insider Sold Shares Worth $2,157,683, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/adaptive-biotechnologies-insider-sold-shares-075816175.html", "source_name": "MT Newswires", "published_at": "2026-07-07T07:58:16+00:00", "published_display": "07 Jul 2026 07:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Russell Index Removal Reshape the Bull Case for Adaptive Biotechnologies (ADPT)?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Adaptive Biotechnologies Corp. \u2013 DUS:1HM", "summary": "The article focuses on the enterprise value to EBIT forward for Adaptive Biotechnologies Corp. (DUS:1HM), listed on the Dusseldorf Stock Exchange. It provides a financial overview and market data for the company's stock.", "url": "https://www.tradingview.com/symbols/DUS-1HM/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T01:10:13", "published_display": "07 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies CCO Susan Bobulsky sells $10,714 in stock", "summary": "Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 487 shares of the company's common stock for $10,714 on July 1, 2026, as per a Rule 10b5-1 trading plan. The sale occurred while the stock was near its 52-week high and considered overvalued by InvestingPro.", "url": "https://www.investing.com/news/insider-trading-news/adaptive-biotechnologies-cco-susan-bobulsky-sells-10714-in-stock-93CH-4778000", "source_name": "Investing.com", "published_at": "2026-07-07T01:08:57", "published_display": "07 Jul 2026 01:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies CPO Francis Lo sells $2.16m in stock", "summary": "Francis Lo, Chief People Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold over $2.16 million in stock across two days in July 2026, executed under a Rule 10b5-1 trading plan. Concurrently, Lo acquired shares worth approximately $661,885 through exercising stock option", "url": "https://www.investing.com/news/insider-trading-news/adaptive-biotechnologies-cpo-francis-lo-sells-216m-in-stock-93CH-4778001", "source_name": "Investing.com", "published_at": "2026-07-07T01:08:57", "published_display": "07 Jul 2026 01:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells 487 shares under 10b5-1 plan", "summary": "Adaptive Biotechnologies Corp's Chief Commercial Officer, Susan Bobulsky, sold 487 shares of common stock at $22.00 per share, totaling $10,714. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025. Following the sale, she still", "url": "https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-dac1586f695e.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:08:57", "published_display": "06 Jul 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (ADPT) CPO trades 95,842 shares under 10b5-1 plan", "summary": "Adaptive Biotechnologies Corp's Chief People Officer, Francis Lo, executed pre-planned stock option exercises and share sales totaling 95,842 shares between July 1-2, 2026. These transactions, made under a Rule 10b5-1 trading plan adopted in September 2025, involved selling share", "url": "https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-4793612f8acd.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:08:57", "published_display": "06 Jul 2026 23:08", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Adaptive Biotechnologies Corp. \u2013 DUS:1HM", "summary": "This article provides financial information for Adaptive Biotechnologies Corp. (DUS:1HM) on the Dusseldorf Stock Exchange. It specifically highlights the \"Price to sales forward\" metric under its financials section. The content is brief and appears to be a stub or a section of a ", "url": "https://www.tradingview.com/symbols/DUS-1HM/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T22:08:57", "published_display": "06 Jul 2026 22:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Adaptive Biotechnologies Corp. \u2013 HAM:1HM", "summary": "This article displays the \"Price to sales forward\" financial metric for Adaptive Biotechnologies Corp. (HAM:1HM) as listed on the Hamburg Stock Exchange. The current market status is closed, with no trades observed. The data is provided by ICE Data Services and FactSet Research S", "url": "https://www.tradingview.com/symbols/HAM-1HM/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T01:39:30", "published_display": "06 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Adaptive Biotechnologies Corp. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold stocks of Adaptive Biotechnologies Corp. (1HM), traded on the Frankfurt Stock Exchange. The ETFs are sorted by their market value of the Adaptive Biotechnologies Corp. shares they hold, providing details such as is", "url": "https://www.tradingview.com/symbols/FWB-1HM/etfs/", "source_name": "TradingView", "published_at": "2026-07-04T11:41:55", "published_display": "04 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADPT - Adaptive Biotechnologies Corp Earnings", "summary": "This article provides a comprehensive financial overview of Adaptive Biotechnologies Corp (ADPT), detailing its stock performance, key financial metrics, and earnings information. It highlights the company's recent earnings surprise, insider and institutional ownership, and vario", "url": "https://finviz.com/stock?t=ADPT&p=d&ty=ea&utm_source=averageinsider&utm_medium=button&utm_content=ratio_drilldown&utm_term=ADPT", "source_name": "Finviz", "published_at": "2026-07-03T10:10:03", "published_display": "03 Jul 2026 10:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harlan Robins sells 116,160 ADPT shares (ADPT) per Form 144 filing", "summary": "Harlan Robins, an insider at Adaptive Biotechnologies Corp (ADPT), filed a Form 144 disclosing the proposed and recent sales of 116,160 shares of Common Stock. This filing details sales on three separate occasions in the past three months, with values totaling over $1.9 million. ", "url": "https://www.stocktitan.net/sec-filings/ADPT/144-adaptive-biotechnologies-corp-sec-filing-653c4907e102.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:10:13", "published_display": "02 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Francis Lo plans ADPT share sales (NASDAQ: ADPT) under Form 144", "summary": "Francis Lo has filed a Form 144 to report proposed dispositions of Adaptive Biotechnologies Corp (ADPT) common stock. The filing details an exercise of stock options for 179,039 shares and a grant of 20,221 Restricted Stock Units, along with two prior 10b5-1 sales totaling over $", "url": "https://www.stocktitan.net/sec-filings/ADPT/144-adaptive-biotechnologies-corp-sec-filing-c0394246a84b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:41:04", "published_display": "01 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADPT (NASDAQ: ADPT) insider sold shares via 10b5-1 plan in June 2026", "summary": "An insider at Adaptive Biotechnologies Corp (NASDAQ: ADPT), Susan Bobulsky, executed three 10b5-1 sales in June 2026, totaling 21,000 shares with combined proceeds of $395,500. These routine transactions were filed via Form 144 and do not indicate new material information about t", "url": "https://www.stocktitan.net/sec-filings/ADPT/144-adaptive-biotechnologies-corp-sec-filing-fa9786851527.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:41:04", "published_display": "01 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive biotechnologies CCO Sharon Benzeno sells over $3.5m in stock", "summary": "Sharon Benzeno, CCO of Adaptive Biotechnologies Corp, sold over $3.5 million worth of company stock in late June through a pre-arranged trading plan. These sales followed the exercise of stock options worth approximately $885,555. The company recently reported strong Q1 2026 reve", "url": "https://m.za.investing.com/news/stock-market-news/adaptive-biotechnologies-cco-sharon-benzeno-sells-over-35m-in-stock-93CH-4350913?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T08:38:58", "published_display": "01 Jul 2026 08:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Adaptive Biotechnologies Corp For: 30 June By Investing.com", "summary": "This article reports on the filing of Form 4 for Adaptive Biotechnologies Corp for the period ending June 30. It focuses solely on this regulatory filing, indicating an insider transaction or change in ownership that companies are required to disclose. The article is very brief, ", "url": "https://au.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-for-30-june-93CH-4512472", "source_name": "Investing.com Australia", "published_at": "2026-07-01T08:38:58", "published_display": "01 Jul 2026 08:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (ADPT) CCO trades shares under 10b5-1 plan", "summary": "Sharon Benzeno, Chief Commercial Officer for Immune Medicine at Adaptive Biotechnologies (ADPT), exercised stock options and sold a total of 165,802 shares in open-market transactions on June 26 and 29, 2026. These transactions, executed under a pre-arranged Rule 10b5-1 trading p", "url": "https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-4c42b6648cad.html", "source_name": "Stock Titan", "published_at": "2026-07-01T08:38:58", "published_display": "01 Jul 2026 08:38", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Adaptive Biotechnologies Corp For: 29 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Adaptive Biotechnologies Corp (ADPT) for June 29. The brief piece indicates insider trading activity for the company on the specified date.", "url": "https://ng.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-for-29-june-93CH-2579136", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T01:11:59", "published_display": "01 Jul 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Adaptive Biotechnologies (NASDAQ: ADPT) exercises options and sells shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOcHpOSWFNQVVNRi1rVmlxTDhVa05Mdlh1R2doaU9wejdOVzZKLVRnNUxyR3JZMWZsT3BHTGs3bzE4Y1I4NS1wWnRJa29kYVRuOGFoTU43X2dtV2t5VkZCelhTSEtmc0VLUzNiZFhYQnBWekdpNW5RN1dpblFuQ0w0MHl5ZVd0dy1Hb3hacTZIbVVsWl8xdkdBdUdZSnZHbEtRME5oUkVZNUkwWG5ZT3BYV1R1TUJNczF4YzUyX3ZZenE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider sells shares under 10b5-1 plan \u2014 ADPT (NASDAQ: ADPT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPWEFnZmJCUFg4OC1mc1RSdzJpa1dseFlDb19zcDdWN1VBQWNNVEM5eDhoMTNfMzUzRThuQUdnNEhWY216Z1NBdlB3RTYxal9SV01PUmhtdG04N2ZYei01Nkhxa0w5bFI4RzF0c0FaVFlRdXREc2czbVVrOG1vem5ReUFxbFBTSmdzN1RuR3YzTzl5QU1LYWlyRHdyU2tscVNJYWUxNnY5Sk9Sdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOeVdaMlFzeXBIZHJ6d0V4X3lObzUyX0wzUUFYWlJ4Q1lfV2F2bFY2LWRmaTNNMUpSWV9ZN2todkQxVkJKUGRsYjBxYjN3VDhraGp0bkdVbGRNbmlPWTZBZ0EyZGxDV3Q3UC1nc18tSDU4dHc3V0hYUGVCS1I0OWd6ZkVqTE1NSGlYN3dKT0hDemxpc3prejBKMTkzdw?oc=5", "source_name": "Market source", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Adaptive Biotechnologies Corp SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPLUVoeXBGWFZMWTdDT01wZ3JxWFdnWEl3bEwtQ253Z1pUYVBhd280RkY5aGNkMzhtYkNPODBwU1pZa3RIUmxHOHByTTBRanZNZTQyQW15a3l4U1Qwdk5aSmxqZG8ybmhkSXhfY2xaeE4tMkpYV1F3UU9yQW53d3l0M2lIb1BzZXF4VHNrY1VmODZ6em9YLS04N3F6S0xwZVE4Y3NTRjloLVhfQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies Issues $345 Million Convertible Notes", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/adaptive-biotechnologies-issues-345-million-213858102.html", "source_name": "MT Newswires", "published_at": "2026-06-22T21:38:58+00:00", "published_display": "22 Jun 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies Insider Sold Shares Worth $1,847,942, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/adaptive-biotechnologies-insider-sold-shares-081002684.html", "source_name": "MT Newswires", "published_at": "2026-06-18T08:10:02+00:00", "published_display": "18 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies raises $300M zero-interest debt, buys back stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNcWxXcDFKaDM2VXBYZ0lHZGd2TEhpTFoxOTBRdlNHZjNWMXliWTJhRWdKRDFDemNRRHQ0cVRRV0F1U3V4YVJiZnVwdHRZLWhwR01oSW83eVpsZTRxS0poc2tXYi01NURXSWtkNmFXY08xRHNncVl0NU1QRHNRTEplOHJrSHBjaTIzSnpKQzB6T0YxWExVLXVLemdrZU9ZUXYwazVhZWdMOWgzMGY1dVpzNzBraDQ4ZWdQVEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies lines up $250M note deal to repay debt, buy back shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOOVhCd1BNYWRMOHNwQU9pZ2l6ci1OTnFDVnN6ZjBtWHpNUUJGbEtvNlg5WllYcF9MTFNPVWZfTmF6MktsN05SX2ZwTV9yTVFlaVJuSmxlbW1HVi1wR1VZMlBTRUNRWE56MXZNN3BVbW9UdmJBTTdfZmZGeDdZaE8zYXVFNVo3S3B5RUo5Q3pFcFhfaEUwUHRlSDZOZkt4NWdBVUR2aGVkVzZhMGVWbUtMV1VJSVhtSXNmcThaZ2hTYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (NASDAQ: ADPT) to sell $250M converts and explore MRD\u2013Immune Medicine split", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNcjRaOVF5SERnWHhfczlsQ1RSMTNTaTVsa3lKWnhXZGJsOUVfdWV5dHVQTzRnVVZVNEpPV3Z0S2JXNXlmQ016VUFReXVtamdycXhVeE5XdUx0N0tUQWR3cGVUQ1ozOFVyajZsc3UxTTBYUTlTeDFaTHhYWGJTdjZtNE52bGRNUndtRlZ5cjEwTzJGZ0ZtNmQ4anBOWElZSDNwN1ZVR0tjcWdwVkNEX0lYdE1PTkhBODluYXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPRHNaNHJZTmk5SnVxdk85cWw1SnFnVEc1WnA4WG5tWFYxVDRmVTdEemNZMWw3OTZwLTR3MUZIUkpzUGZkZnoxTHZqb2twaGprRS1RZzRUT1Q3M1k0Z3pQX01pdW9wVlYyVXMxS3RuMk1uZFZ2N2wtWEQzUVIxdXVwaUg5NlBQRElsQnVta09xenhuWHZ0NUdxREl3YlpIM2tLRFZ3bQ?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Adaptive Biotechnologies (ADPT) Narrative Is Shifting Around A US$20 Fair Value Anchor", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPVWpNbm1FamlxSkhFQ1ctOVRSWWMyMWlsZGtnekNvRVhfX0lzSGFWdV9XU3pmaDlaYjlIeF9YdDJHS0pob0RxVllHQUxVUHAyV19Lb0lzYW1ZZDJSQmVvcENPb3VnZjNDWHJJaUZCaUZ6Ni1ETWJmWVNCUkpoQ2R6bmcxSmRqNG1RSWJKNmp0TmlLWTMyN2JXR2hraDRaWkFHTXp3bnN3OHhnWm01T3pNQW9sWQ?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Adaptive Biotechnologies (ADPT) Attractively Priced After Recent Share Price Weakness?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive lifts 2026 MRD outlook after $70.9M quarter, 41% test gain", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxONUQ2ZzVob3JoMm5Wa29HdjBacERGaWdfXzRUSi1qYWp0UTdQSXpPcFpWdS11NzR4T3pPY0I0Y21vUUFiSmUwTXZOMVJEQmhMLXlvNnNlU3ZlRGUtX3hEenpiT2cyYzNoLUF6QkVuczlZT0dIc1JnYU1Dc0JWeS1BVnJtYXNxck9Sb212Y2FfMzVIaWVEUWRZbXVkMzhldk1Ob2Z0QXd3cDdHYnQ5VllQbHh1WGpTTUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWEVXNllESWhPWDllcG4wMXFWZTloOTNZSXlIZHB4R1dMbEI1Q2VCTHJpdEFaQkJPWnZGb1dhWW10SWhScGhNUndwYTdMY282SWZ0QUtxYUlYUngwdXJWa2g1Ym5QQ2Z2M1o5cEtkRzFYVDBKemJycU9Jb1VUckJVRDhkel9Tb3BBTG1YZU5FdU54V1FMX19ReXZoSFE1VVFOWWdpZUY1U1k?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sale At Adaptive Biotechnologies Versus clonoSEQ Growth And Valuation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 96, "total_relevant": 48, "sentiment_summary": {"positive": 7, "negative": 6, "neutral": 35, "score": 50, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 19.25, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 7}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 21.06, "latest_week": "2026-07-10", "one_week_move": -0.6, "four_week_move": 19.7, "twelve_week_move": 45.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.459271, "market_dynamics_buy_signal": false, "relative_strength": 19.221284, "fair_value_gap": 137.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 57.3274, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.6% over one week, +19.7% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 50, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 16}, {"label": "simplywall.st", "count": 5}, {"label": "MT Newswires", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "Market source", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "Investing.com South Africa", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 7}, {"label": "Balance sheet", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.6% over one week, +19.7% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Planned 5,000-share stock sale for ADPT (NASDAQ: ADPT)"}], "updated_at": "2026-07-17T09:45:08.898572+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}